Sacubitril/Valsartan Sodium Tablets (Entresto) is an angiotensin receptor-neprilysin inhibitor with an innovative mechanism, playing a crucial role in the field of heart failure treatment.
Dosage and Administration, Recommended Doses of Sacubitril/Valsartan Sodium Tablets (Entresto)
Treatment Doses for Chronic Heart Failure
The regular dosage regimen for adults is an initial dose of 50mg taken orally twice a day.
Based on the patient’s tolerance, the dose can be gradually increased to a maintenance dose of 200mg per dose within 2-4 weeks. All doses (50mg, 100mg, 200mg) are administered twice a day.
If intolerance occurs, dose adjustment or temporary discontinuation of the drug is required in a timely manner.
Pediatric Dosage Regimen
Body weight below 40kg: Initial dose of 0.8mg/kg, gradually increased to a target dose of 3.1mg/kg.
Body weight above 40kg and below 50kg: Initial dose of 0.8mg/kg, increased stepwise to 50mg, 100mg, and a target dose of 150mg.
The minimum dose of pediatric granular tablets is 12.5mg, and the dose must not be further reduced.
Treatment Doses for Hypertension
The regular adult dose is 200mg taken orally once a day.
The dose can be appropriately adjusted according to age and symptoms, with the maximum dose not exceeding 400mg once a day.
Criteria for Dose Escalation
No episodes of asymptomatic hypotension.
Systolic blood pressure stably maintained above 95mmHg.
Serum potassium concentration below 5.4mEq/L.
Estimated glomerular filtration rate (eGFR) not less than 30mL/min/1.73m², and the decrease range not exceeding 35%.
Patients Requiring Cautious Evaluation
Patients with renal impairment (eGFR < 90mL/min/1.73m²).
Patients with moderate hepatic impairment.
Patients with hypotensive status.
Medication for Special Populations of Sacubitril/Valsartan Sodium Tablets (Entresto)
Patients with Renal Impairment
Mild to moderate renal impairment: Closely monitor blood pressure, serum potassium, and renal function indicators.
Severe renal impairment: Strictly evaluate the necessity of medication, and enhance monitoring during the medication period.
Dialysis patients: Start with a low dose, adjust the dose slowly, and strengthen monitoring.
Patients with Hepatic Impairment
Severe hepatic impairment (Child-Pugh Class C): Use of this product is prohibited.
Moderate hepatic impairment: Strictly weigh the pros and cons, and enhance medication safety monitoring.
Elderly Patients
Due to the natural decline of physiological functions, special attention should be paid to changes in blood pressure, serum potassium, and renal function.
Greater caution is required, especially in the initial stage of medication and the dose escalation stage.
Pregnant and Lactating Women
Pregnant women: Use is strictly prohibited; if pregnancy is detected during medication, the drug must be discontinued immediately.
Lactating women: It is recommended to suspend breastfeeding during the medication period.
